Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy

被引：0
|
作者：
Ellsworth, Patrick [1 ,2 ]
Chen, Sheh-Li [3 ]
Key, Nigel [1 ]
Abajas, Yasmina [2 ]
Ma, Alice [1 ]
机构：
[1] Univ N Carolina, Dept Med, Div Hematol Oncol, Houpt Bldg,CB 7305,170 Manning Dr,3rd Floor, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pediat, Div Pediat Hematol Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 01期
关键词：
OBI-1; SEQUENCE; SAFETY;
D O I：
10.1111/hae.14111
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E147 / E150
页数：4
相关论文
共 50 条
  • [21] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
  • [22] The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors
    van Velzen, Alice S.
    Eckhardt, Corien L.
    Streefkerk, Nina
    Peters, Marjolein
    Hart, Daniel P.
    Hamulyak, Karly
    Klamroth, Robert
    Meijer, Karina
    Nijziel, Marten
    Schinco, Piercarla
    Yee, Thynn T.
    van der Bom, Johanna G.
    Fijnvandraat, Karin
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (03) : 543 - 550
  • [23] Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
    Scharrer, I
    Brackmann, HH
    Sultan, Y
    Abshire, T
    Gazengel, C
    Ragni, M
    Gorina, E
    Vosburgh, E
    Kellermann, E
    HAEMOPHILIA, 2000, 6 (06) : 614 - 618
  • [24] The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update
    Lusher, JM
    Roth, DA
    HAEMOPHILIA, 2005, 11 (03) : 292 - 293
  • [25] Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B
    Wang, C.
    Young, G.
    HAEMOPHILIA, 2018, 24 (03) : 414 - 419
  • [26] Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies
    Volkers, Peter
    Hanschmann, Kay-Martin
    Calvez, Thierry
    Chambost, Herve
    Collins, Peter W.
    Demiguel, Virginie
    Hart, Daniel P.
    Hay, Charles R. M.
    Goudemand, Jenny
    Ljung, Rolf
    Palmer, Ben P.
    Santagostino, Elena
    van Hardeveld, Ella M.
    van den Berg, Marijke
    Keller-Stanislawski, Brigitte
    HAEMOPHILIA, 2019, 25 (03) : 398 - 407
  • [27] Treatment of acquired haemophilia with recombinant porcine factor VIII: A successful strategy in a patient with unstable angina
    Owen, Mary
    Gidley, Gillian
    Horn, Elizabeth H.
    HAEMOPHILIA, 2019, 25 (02) : E94 - E97
  • [28] Short-term efficacy of recombinant porcine factor VIII in patients with acquired factor VIII inhibitors
    Abou-Ismail, M.
    Vuyyala, S.
    Prunty, J.
    Schmaier, A.
    Nayak, L.
    HAEMOPHILIA, 2019, 25 : 3 - 3
  • [29] Recombinant Fusion Factor VIII-Fc Fusion Protein in Severe Haemophilia A Patients
    Le Quellec, Sandra
    HEMATOLOGIE, 2014, 20 (06): : 304 - 306
  • [30] Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients
    Tarantino, M. D.
    Cuker, A.
    Hardesty, B.
    Roberts, J. C.
    Sholzberg, M.
    HAEMOPHILIA, 2017, 23 (01) : 25 - 32
12345